摘要
目的:通过体外实验,研究重组人类生长激素对胃癌细胞的增殖的影响。方法:实验分为空白组,重组人类生长激素组,奥沙利铂组和重组人类生长激素+奥沙利铂组。用不同浓度的重组人类生长激素处理SGC-7901细胞,采用MTT法和流式细胞仪检测人胃癌细胞株的细胞抑制率,细胞周期和DNA抑制率。结果:体外实验结果表明,重组人类生长激素对SGC-7901细胞株增殖没有明显的促进作用,重组人类生长激素组和空白组以及重组人类生长激素+奥沙利铂组和奥沙利铂组之间没有统计显著性(P>0.05),细胞抑制率和停止生长的细胞在G0-G1期明显增加(P<0.01),同时重组人类生长激素+奥沙利铂组和空白组以及奥沙利铂组在S期,细胞数依次下降,DNA抑制率依次增加。重组人类生长激素+奥沙利铂组与奥沙利铂组相比,细胞抑制率有明显上升趋势。结论:体外实验表明,重组人类生长激素并不加快人类胃癌细胞的增殖,与抗癌药物一同使用时,有增加治疗功效的作用。
Objective： To investigate the effects of recombinant human growth hormone （rhGH） on growth of human gastric cancer cell line in vitro. Methods： Cells were divided into control group, rhGH group, oxaliplatin （L-OHP） group and rhGH＋L-OHP group. Cell inhibitory rate, cell cycle and DNA inhibitory rate of human gastric cancer line SGC-7901, at different concentrations of rhGH treatment were detected by cell culture, MTT assay and flow cytometry. Results： There was not distinctly accelerated effect of rhGH on multiplication of SGC-7901 cell line in vitro. There was no statistical significance between rhGH group and control group, or between rhGH＋L-OHP group and L-OHP group （P〉0.05）. Cell inhibitory rate and cell arrested in G0-G1 phase increased. Meanwhile, cells in S phase distinctly decreased and DNA inhibitory rate increased in rhGH＋L-OHP group in comparison with L-OI-IP group （P〈 0.01 ）. Conclusion： rhGH does not accelerate the multiplication of human gastric cancer cells. It may increase the therapeutic efficacy when used in combination with anticancer drugs.
出处
《现代生物医学进展》
CAS
2011年第20期3849-3852,共4页
Progress in Modern Biomedicine
关键词
重组人类生长激素
胃癌细胞
增殖
Recombinant human growth hormone （rhGH）
Human gastric cancer cell line
Growth
